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Background: Prostate cancer is one of the most common cancers in men in US and European 
countries. Despite having a favorable prognosis, the incidence of incurable metastatic disease 
and mortality in the US is about 28,000 per year. Although hormone-based androgen deprivation 
therapies typically result in rapid responses, nearly all patients eventually develop progressive 
castration-resistant disease state. With readily available prostate-specific antigen (PSA) testing, 
most of these patients are asymptomatic and manifest progression simply as a rising PSA. In 
patients with castration-resistant prostate cancer (CRPC), the median survival is about 1–2 years, 
with improvements in survival seen mostly with docetaxel-based regimens. The purpose of this 
article is to review the recent developments in the treatment of advanced CRPC.
Recent findings: Since the two landmark trials (TAX-327 and Southwest Oncology Group 
99–16) in CRPC, several newer cytotoxic drugs (epothilones, satraplatin), targeted agents 
  (abiraterone, MDV3100) and vaccines have been tested in phase II and III setting with promising 
results.
Conclusions: The role of newer agents in the treatment of CRPC still needs to be validated by 
phase III trials, which are currently ongoing. Whilst the novel biomarkers, ‘circulating tumor 
cells’, have been shown to provide important prognostic information and are anticipated to 
be incorporated in future clinical decision-making, their exact utility and relevance calls for a 
larger prospective validation.
Keywords: castration-resistant prostate cancer, novel therapies, mechanisms of resistance, 
circulating tumor cells
Introduction
Prostate cancer is a highly prevalent and clinically heterogeneous disease. It is the 
most common cancer for men in the US with an estimated 192,280 new cases diag-
nosed in 2009. It also is the second leading cause of cancer deaths accounting for 9% 
of all cancer-related death in men.1 It has an exceptionally high incidence/mortality 
ratio compared to the other leading causes of cancer deaths.2 Rates of detection of 
prostate cancers vary widely across the world, with South and East Asia detecting 
less frequently than in Europe, and the United States. It is a highly curable disease if 
diagnosed at an early stage and 5-year relative survival rates based on Surveillance, 
Epidemiology, End Results (SEER) database’s cancer statistics were 100.0% for both 
localized and regional disease, and 30.6% for distant disease.3
Despite having a favorable prognosis, there is a subgroup of prostate cancer 
patients who develop incurable metastatic disease (estimated to be around 28,000 
each year in the US) and ultimately succumb to death as a result of advanced disease. OncoTargets and Therapy 2010:3 40
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Although androgen-deprivation therapies typically result 
in rapid responses, nearly all patients eventually develop 
progressive castration-resistant disease state. Several treat-
ment options have been described for these patients with 
castration-resistant prostate cancer (CRPC) as listed in 
Table 1. However, most of the secondary hormone manipula-
tion techniques despite achieving castrate levels of testoster-
one, provide temporary disease control only, and on average, 
after 12–18 months, the malignant cells develop resistance, 
with a reported median overall survival of approximately 
30 months.4
Analysis of tumor specimens from patients with CRPC 
has shown several mechanisms adapted by cancer cells 
to reactivate the androgen receptor (AR) signaling at   
sub-physiological serum concentrations of androgens or 
even in the presence of AR antagonists.5 Several new drugs 
targeting these pathways are being developed and currently 
being tested in clinical trials.
In this article, we review recent developments in the treat-
ment of advanced CRPC. We performed a systematic review 
of peer-reviewed publications identified through searches of 
MEDLINE/PubMed from 2003 to September 2009. We also 
included results of the relevant clinical trials presented at the 
annual oncology meetings (eg, Annual Meeting of American 
Society of Clinical Oncology [ASCO]). The ongoing phase II 
and phase III trials for first- and second-line chemotherapy 
for CRPC were searched from the US National Institute of 
Health’s web resource, clinicaltrials.gov, which is a registry 
of clinical trials conducted in the United States and world-
wide. Keywords were used alone and with the modifiers 
of treatment, novel therapies, castration-resistant prostate 
cancer, castrate-resistant prostate cancer, circulating tumor 
cells, and biomarkers. Bibliographies from these references 
were reviewed. Criteria used for study selection included 
study design, English language, relevance to clinicians, and 
validity based on the venue of publication.
Biomarkers of disease response  
to treatment
In prostate cancer, reliable markers of disease status are 
important for selecting and monitoring treatment. Since most 
men with advanced CRPC have bone metastasis, these lesions 
are difficult to assess using the standard response evaluation 
criteria in solid tumors. Hence several other disease markers 
such as decrease in serum prostate-specific antigen (PSA; 
eg, major and minor responses of 50% and 25% to 49% 
PSA decrease from baseline, respectively), symptomatic 
improvement in bone pain (visual analog scale) or quality of 
life questionnaires have been used in clinical trials as indica-
tors of clinical response and benefit. More recently, by using 
reverse transcriptase-polymerase chain reaction (RT-PCR) for 
PSA mRNA, detecting circulating PSA-producing prostate 
cancer cells have been shown in preliminary studies to have 
prognostic significance6 and this may become a useful tool 
in assessing response to treatment in the future.
Serum prostate-specific antigen
Most clinical trials7,8 in prostate cancer have used an improve-
ment of 50% in the serum PSA as a marker of response. 
This is also commonly used to guide treatment decisions 
on individual patients. In about 5%–10% of patients, whose 
prostate cancers are associated with low serum PSA, a 
decline in PSA cannot be used as an indicator of response. 
Criteria for disease progression when using changes in PSA 
has been well defined by the Prostate Cancer Clinical Trials 
Working Group (PCWG2)7 and the Prostate-Specific Antigen 
Working Group (PSAWG)8 and this has also been validated 
by data-sets of two large Southwest Oncology Group Trials 
(SWOG 9346 and 9916).9 The following definitions are used 
to define progression:
1.  In patients whose PSA has not decreased, progressive 
disease is a 25% increase over the baseline (on-study) 
and an increase in the absolute-value PSA level by at 
least 2 ng/mL, which is confirmed by a second value.
2.  In patients whose PSA has decreased but has not reached 
response criteria, progressive disease would be consid-
ered to have occurred when PSA increases 25% over the 
post-treatment nadir.
It is important to note that there can be an initial 
  transient surge in serum PSA during the first six to eight 
Table 1 Current treatment options for patients with castration-
resistant prostate cancer2
Secondary hormonal therapies
withdrawal responses (eg, antiandrogens, megestrol acetate)
Antiandrogen administration (flutamide, bicalutamide, nilutamide)
Adrenal suppressants (ketaconzole, aminoglutethimide)
Glucocorticoids (eg, dexamethasone, prednisone)
estrogens (eg, DeS, fosfestrol, estramustine)
Bisphosphonates (Zoledronate)
external-beam radiation therapy
Bone-seeking radiopharmaceuticals (samarium, strontium)
Chemotherapies (eg, mitoxantrone, docetaxel)
experimental therapies
Abbreviation: DeS, diethylstilbestrol.OncoTargets and Therapy 2010:3 41
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weeks of treatment followed by disease stabilization and 
decrease in PSA.
Serum clusterin levels in CrPC
Clusterin, also known as apolipoprotein J, is a stress-induced 
cyto-protective chaperone protein expressed in virtually all 
human tissues.10 Clusterin over-expression is demonstrated 
in various human malignancies including prostate, breast, 
lung, bladder, kidney, and colon cancers.11 In prostate cancer, 
clusterin levels are low in hormone-naïve tissue, but increase 
significantly after hormone therapy.12 Clusterin levels have 
also been correlated with preoperative PSA value and also 
the pathological grade on both biopsy and radical prosta-
tectomy specimens.13 Further, clusterin expression has also 
been reported to be a possible predictor for biochemical 
recurrence following radical prostatectomy.14 In a recent 
phase II clinical trial,15 serum levels of clusterin was used a 
biomarker of response and was reported to be significantly 
reduced following treatment with OGX-011, an antisense 
oligonucleotide against clusterin. All these data put together 
suggest that clusterin could be used as a potential diagnostic 
and prognostic indicator and also a marker of response to 
treatment in CRPC with metastases, but needs to be evalu-
ated in larger randomized studies.
Fluoro-dihydrotestosterone positron 
emission tomography
Fluoro-dihydrotestosterone (FDHT) is a biomarker of 
androgen receptor expression in human prostate cancer, 
and has been particularly useful in the setting of advanced 
prostate cancer, when the patient has castrate levels of cir-
culating testosterone in the blood. Two small prospective 
studies have shown the feasibility of using FDHT scan with 
excellent imaging characteristics and a rapid uptake in the 
tumor at metastatic sites expressing androgen receptor with 
acceptable dosimetry.16–18 This scan is currently incorporated 
and compared to fluoro-deoxyglucose (FDG) positron emis-
sion tomography (PET) in a phase I/II study of novel small 
molecule androgen receptor antagonist MDV3100.19 Initial 
reports presented at the 2009 ASCO annual meeting showed 
a 50% decline in the standardized uptake value (SUVmax) 
on FDHT PET observed in 11 out of 12 of patients (92%) 
at 4 and 12 weeks, while six patients (50%) had a decreased 
SUVmax on FDG PET.20
role of circulating tumor cells
Circulating tumor cells (CTCs) are epithelial cells that shed 
from different tumors. The CTC count is based on a test 
that works by using fluorescence labeled antibodies against 
  epithelial cell adhesion molecules combined to microscopic 
iron particles, called ferrofluid. These antibody/ferrofluid 
combinations attach very specifically to CTCs. Powerful 
magnets then “pull” the CTCs out of the blood sample and 
they are then stained with additional bio-molecules and 
chemicals so that they can be positively identified as CTCs. 
This system, approved by the US Food and Drug Administra-
tion (FDA) is commercially available as CellSearch™ for 
monitoring of metastatic prostate cancer, metastatic breast 
and metastatic colorectal cancer patients. In a prospective 
study, De Bono and colleagues21 reported that CRPC patients 
with 5 CTCs per 7.5 mL prior to chemotherapy had a sig-
nificantly shorter median survival compared to those with 
5 CTCs (10 vs 21 months). Also, changes in number of 
CTCs following chemotherapy correlated with prognosis. 
Patients who had 5 CTCs at baseline and at their last assess-
ment had a median survival of more than 26 months, while 
those who had 5 at baseline but then had 5 at their last 
assessment had a median survival of 21 months. In contrast, 
those with 5 CTCs at an early assessment who had 5 at 
their last assessment had a median survival of nine months, 
and those who had 5 CTCs at all assessments had a median 
survival of only seven months. Two recent prospective stud-
ies have also validated that increased levels of circulating 
tumor cells predict worse outcomes in patients with meta-
static CRPC.22 The CTC number, analyzed as a continuous 
variable, has a potential to be used to monitor disease status 
and might be useful as an intermediate endpoint of survival 
in clinical trials. Its role in treatment decisions need to be 
validated prospectively.
Chemotherapy for CRPC
First-line chemotherapy for CrPC
Mitoxantrone, estramustine, and docetaxel are the three 
drugs which are currently approved by FDA for first-line 
chemotherapy in CRPC. Two pivotal trials which showed a 
survival benefit with Docetaxel have established the combi-
nation of Docetaxel and prednisone as the standard of care 
for men with CRPC.
In the landmark TAX-327 trial, 1006 chemotherapy-naïve 
CRPC patients were randomized to three different treatment 
arms – docetaxel 30 mg/m2 every week, docetaxel 75 mg/m2 
every three weeks and mitoxantrone 12 mg/m2 every three 
weeks. All patients received prednisone 5 mg orally twice 
a day. Patients receiving docetaxel every three weeks had 
a significant improvement of survival compared to weekly 
docetaxel and mitoxantrone (18.9 months vs 16.5 months; OncoTargets and Therapy 2010:3 42
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P  0.009). PSA response, pain control and quality of life 
were also significantly better with docetaxel every three 
weeks compared to mitoxantrone.23 An update of the results of 
TAX-327 trial in 2007 showed a persistence of a survival ben-
efit of docetaxel every three weeks compared to mitoxantrone 
and no survival benefit with the weekly docetaxel. At three 
years, survival was 17.2% for docetaxel every three weeks 
compared to 12.8% with mitoxantrone (P = 0.005).24
The Southwest Oncology Group (SWOG) 99-16 study 
also shows survival benefit with Docetaxel. 674 patients with 
metastatic CRPC were randomized to docetaxel/estramustine 
and Mitoxantrone/prednisone arms. Treatment regimen was 
280 mg of estramustine three times daily on days 1 through 5, 
docetaxel 60 mg/m2 on day 2 in the docetaxel arm and 12 mg 
of mitoxantrone mg/m2 on day 1 plus 5 mg of prednisone 
twice daily in the mitoxantrone arm. Docetaxel was reported 
to be superior to mitoxantrone with a median survival of 
17.5 months vs 15.6 months (P = 0.02), median time to pro-
gression (6.3 vs 3.2 months; P  0.001) and PSA declines 
of 50% (50% vs 27%; P  0.001). However, there was no 
significant objective tumor response difference between the 
two arms.25 These two trials showed a 20%–24% reduction 
in mortality in patients with CRPC docetaxel doublets (che-
motherapy combinations).
Several chemotherapy agents in combination with 
docetaxel have been investigated in the first-line setting 
to improve PSA response and efficacy. Though there has 
been evidence of activity in phase II studies, none have 
demonstrated superiority to docetaxel/prednisone in phase 
III trials.
Docetaxel-based combinations
Docetaxel plus vinorelbine
Vinorelbine, a semisynthetic vinca alkaloid, and docetaxel 
have demonstrated synergy in tumor cell lines and animal 
models. Efficacy and tolerability of the combination of 
vinorelbine and docetaxel for chemotherapy-naïve CRPC 
has been studied in several phase II trials. In a study of 
21 patients treated with vinorelbine, 20 mg/m2 followed 
by docetaxel, 25 mg/m2, on days 1 and 8 of a 21-day cycle, 
18 patients who were evaluable for biochemical response 
with 11 patients having a 50% reduction in PSA. Of five 
patients with measurable disease, three were evaluable: 
one patient had a complete response, and two had partial 
responses at the site of measurable disease.26 Similar results 
were noted in another study with same chemotherapy regi-
men. In addition to PSA response, 42% of patients achieved 
a significant change in Karnofsky performance score (KPS) 
and positive pain response.27 More recently, two docetaxel 
doublets were compared in a randomized phase II trial. In 
this study, 64 chemotherapy-naive patients with CRPC were 
randomized to a three-week regimen of docetaxel (20 mg/m2, 
days 1 and 8) and vinorelbine (25 mg/m2, days 1 and 8) or 
docetaxel (60–70 mg/m2, day 1) and estramustine (280 mg 
oral thrice daily days 1–5) arms. The docetaxel/vinorelbine 
arm was inferior compared to the docetaxel/estramustine 
arm in terms of objective response rate (33% vs 67%), PSA 
response rate (33% vs 43%), and median survival (16.2 vs 
19.7 months).28
Docetaxel plus capecitabine
Capecitabine has been combined with docetaxel because 
of its potential synergy with docetaxel. In a phase II study 
with 30 patients, docetaxel 36 mg/m2 administered on days 1, 
8, and 15, and capecitabine 1250 mg/m2 taken orally on days 
5–18 every 28 days was shown to have a 50% PSA decline 
sustained for at least four weeks in 19/27 (71%) patients) 
with a 90% PSA decline in 8/27 (30%) patients. Partial 
response per Response Evaluation Criteria in Solid Tumors 
(RECIST) was noted in 5/10 (50%) evaluable measurable-
disease patients. The regimen was tolerable with one grade 
4 neutropenia and two patients with grade 3 hand-foot syn-
drome and no treatment-related deaths.29
Docetaxel plus thalidomide
Preclinical models have demonstrated significant activity 
of the combination of docetaxel and thalidomide in CRPC. 
In a phase II trial, 75 patients were randomly assigned to 
receive either docetaxel 30 mg/m2 weekly for three weeks, 
followed by a one-week rest period (n = 25); or docetaxel 
at the same dose and schedule, plus thalidomide 200 mg 
orally each day (n = 50). This combination showed that the 
proportion of patients with a greater than 50% decline in 
PSA was higher in the docetaxel/thalidomide group (53% 
in the combined group, 37% in docetaxel-alone arm). 
However, the progression-free survival (PFS) or overall 
survival (OS) was not different in the two groups. Toxici-
ties except thromboembolic events were comparable to both 
groups. While there were no thromboembolic events in the 
docetaxel-alone group, 12 of the first 43 patients treated with 
the docetaxel/thalidomide combination developed either 
venous thrombosis (n = 9) or transient ischemic attack or 
stroke (n = 3). There was no thrombosis in the subsequent 
patients after the initiation of prophylactic anticoagulation 
with low-molecular-weight heparin.30 Currently, a phase II 
trial is underway evaluating the combination of docetaxel, OncoTargets and Therapy 2010:3 43
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bevacizumab, thalidomide and prednisone in CRPC.19 
  Preliminary results of this trial presented at the 2008 ASCO 
annual meeting are very encouraging. Sixty patients with 
progressive metastatic CRPC and no prior chemotherapy for 
CRPC were treated with docetaxel 75 mg/m2 + bevacizumab 
15 mg/kg day 1, every three weeks; thalidomide 200 mg 
and prednisone 10 mg was given orally daily. Median num-
ber of treatment cycles was 11 (2–46). Fifty-one patients 
(88%) had PSA declines of 50% and 41 patients (71%) 
had a 80% PSA decline. The estimated median PFS was 
18.2 months.
Docetaxel plus carboplatin
Platinum compounds have modest but distinct single-
agent activity in patients with hormone-refractory prostate 
  carcinoma. Its activity in combination with docetaxel was 
evaluated in a phase II study by Oh and colleagues in a 
Cancer and Leukemia Group B (CALGB) multicenter study, 
40 patients were treated with oral estramustine (240 mg 
three times per day for five days), 70 mg/m2 of docetaxel, 
and carboplatin at a dose of area under the curve (AUC) 5. 
Granulocyte colony-stimulating factor (G-CSF) was used 
to minimize the neutropenia associated with this regimen. 
Each cycle was repeated every 21 days. Of the 34 evaluable 
patients, 23 (68%) had a 50% decline in PSA and 20 (59%) 
had a 75% decline. Twenty-one patients had measurable 
disease, with one complete (5%) and 10 partial responses 
(47%), for an overall measurable response rate of 52%. The 
overall median time to disease progression was 8.1 months 
and the overall survival period was 19 months.31
Docetaxel plus epirubicin
Anthracyclines have shown some activity in CRPC as 
reported by the EORTC Genitourinary group.32 Epirubicin, 
at equipotent doses, is associated with quantitatively less 
severe toxicity than its parent compound.32 This agent has 
been studied by EORTC Genitourinary group in a phase II 
trial in combination with docetaxel. Docetaxel 30 mg/m2 and 
epirubicin 30 mg/m2 were administered on a weekly basis for 
a maximum of 24 cycles. The therapy was discontinued after 
the first 12 cycles in the patients who responded or had stable 
disease and was resumed as soon as any signs of progression 
were noted. Of the 38 evaluable patients, 26 (68.4%) achieved 
a 50% decrease in PSA. The median response duration 
was 8.8 months, and the median time to progression was 
7.4 months (95% confidence interval [CI]: 5.6 to 9.6). Pain 
was rapidly reduced in 24 (72.7%; 95% CI: 54.2 to 86.7) 
of the 33 patients who were symptomatic at baseline. The 
regimen was well tolerated. Grade 3 neutropenia occurred in 
15.7% of the patients, grade 3 anemia in 13.1%, and grade 
3 thrombocytopenia in 7.8%.32,33
Docetaxel plus calcitriol
Prostate cancer cells express vitamin D receptor (VDR) 
for 1, 25 dihydroxy vitamin D. VDR activation is linked to 
more than 60 genes promoting pro-differentiation, antipro-
liferation, and apoptotic activity on prostate cancer cells.34,35 
Calcitriol has been shown to potentiate the effect of cyto-
toxic therapy when combined with taxanes. The Androgen-
independent prostate cancer Study of Calcitriol Enhancing 
Taxotere (ASCENT) trial was a double-blind, randomized, 
phase II study of DN-101 (Ascentar; a high-dose formulation 
of calcitriol) and weekly docetaxel compared with docetaxel 
alone. 250 patients with progressive CRPC were randomized 
to weekly docetaxel 36 mg/m2 for three weeks of a four-
week cycle combined with either 45 µg DN-101 or placebo 
taken orally one day before docetaxel. The primary end-
point, 50% PSA decline within six months of enrollment, 
were seen in 58% in DN-101 patients and 49% in placebo 
patients (P = 0.16). Overall, the response rate was 63% for 
DN-101-treated patients and 52% for placebo treated patients 
(P  =  0.07). Patients in the DN-101 group had a hazard ratio 
for death of 0.67 (P = 0.04) in a multivariate analysis. On 
the basis of these results, a phase III trial (ASCENT-2) was 
initiated. This trial differed from the ASCENT-1 trial in that 
the control arm was changed to the standard every three-
week docetaxel regimen. A planned interim analysis found 
excess number of deaths among patients assigned to receive 
DN-101, resulting in termination of the trial.19 At this point 
in time, DN-101’s role in the treatment of prostate cancer 
remains uncertain.
Docetaxel plus oblimersen
The Bcl-2 family of proteins constitutes a critical intracellular 
checkpoint of apoptosis within a distal common cell death 
pathway.36 It is also thought to be involved in resistance to 
conventional cancer treatment. Oblimersen is an antisense oli-
godeoxynucleotide targeted against Bcl2. In a phase II study 
by Tolcher and colleagues, the combination of oblimersen 
sodium (7 mg/kg/day continuous infusion on days 1–8) and 
docetaxel (75 mg/m2 on day 6, every three weeks) produced 
PSA response in 14 of 27 (52%) patients with metastatic 
CRPC with a median survival of 19.8 months. Bcl-2 protein 
expression decreased, with a median of 49.9% in peripheral 
blood mononuclear cells post-treatment, but the individual 
incremental change did not correlate with either steady-state OncoTargets and Therapy 2010:3 44
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concentration of oblimersen or response.37 However, these 
promising findings were not supported by a recently reported 
randomized phase II study by the EORTC.38 In this trial, 115 
patients with metastatic CRPC who had not received previ-
ous chemotherapy, were assigned to three-weekly therapy 
with either oblimersen sodium (7 mg/kg/day, days 1–7) plus 
docetaxel (75 mg/m2, day 5) or docetaxel (75 mg/m2, day 5) 
alone, for up to 12 cycles. The proportion of patients with a 
PSA response was higher in the single-agent docetaxel arm 
than in the docetaxel plus oblimersen sodium arm (46% vs 
37%). Interestingly, oblimersen added to docetaxel was asso-
ciated with an increase in the incidence of grade 3 fatigue, 
mucositis, and thrombocytopenia. Major toxic events were 
reported in 22.8% and 40.7% of patients with docetaxel and 
docetaxel–oblimersen, respectively. Another Bcl-2 inhibitor, 
AT-101, is currently being investigated in phase I/II studies 
with docetaxel.19
Docetaxel plus custirsen (OGX-011)
Several studies have demonstrated clusterin overex-
pression in prostate cancer especially after hormone 
therapy.13,39 Clustein expression has also reported to 
be a possible predictor for biochemical recurrence fol-
lowing prostatectomy.14 An antisense oligonucleotide 
directed against clusterin (custirsen, OGX-011) has been 
developed, and successful downregulation of clusterin 
expression was shown in primary prostate cancers in a 
phase I study.40
Custirsen is further being evaluated in a randomized 
phase II study in combination with Docetaxel and predni-
sone in chemotherapy-naïve CRPC patients and preliminary 
data was reported at the 2009 ASCO annual meeting.15 
Docetaxel 75 mg/m2 every three weeks along with custirsen 
640 mg IV weekly (arm A) was compared to docetaxel 
(arm B). PSA response rate was the primary endpoint; pro-
gression-free survival and overall survival were secondary 
endpoints. Data of 82 patients enrolled between September 
2005 and December 2006 was reported. PSA response 
rate was 58% in arm A and 54% in arm B. Significant 
decrease in mean serum clusterin levels measured on day 1 
of cycle 2 was noted with custirsen (-18% in arm A and 
+8% in arm B; P = 0.0005). After a median follow-up of 
32 months, overall survival (27.5 months vs 16.9 months, 
hazard ratio = 0.60; P = 0.07) showed trend towards supe-
riority with custirsen, while progression-free survival was 
similar between the two arms (7.3 vs 6.1 months). Major 
adverse events noted with custirsen include fatigue, fever, 
rigors, diarrhea, and rash.
Other cytotoxic agents
epothilones
The epothilones are a new class of nontaxane tubulin 
polymerizing agents.41 Two epothilones, ixabepilone and 
patupilone, in clinical studies, have shown significant activ-
ity in men with CRPC.42–45 A phase II study conducted by 
the Southwest Oncology Group (SWOG) included 42 men 
with chemotherapy-naive CRPC who received ixabepilone 
(40 mg/m2) every three weeks.43 PSA decline 50% was 
noted in 14 patients (33%). 72% of PSA responders had 
declines greater than 80%, and two patients achieved an 
undetectable PSA. The estimated median PFS was six months 
and the median survival was 18 months. Major toxicities were 
neutropenia and neuropathy. Phase III trials with Ixabepilone 
are in development.
A randomized multicenter phase II trial of patupilone (at 
two different doses, 8 mg/m2 or 10 mg/m2 given every three 
weeks) vs docetaxel in CRPC is currently underway.19
eribulin
Eribulin mesylate (E7389), a synthetic analog of halichondrin 
B, is a nontaxane inhibitor of microtubule dynamics exerting 
its anticancer effects by triggering apoptosis of cancer cells 
following prolonged mitotic blockage.46 In a multicenter, 
open-label, single-arm, phase II study, patients with meta-
static CRPC, stratified by prior taxane exposure, received 
eribulin mesylate 1.4 mg/m2 on days 1 and 8 of a 21-day 
cycle. No steroid premedication or concomitant medication 
was administered. Of 108 patients evaluable for safety, 58 
were taxane-naïve. Primary endpoint of PSA response rate 
defined as two consecutive 50% decreases in PSA levels 
from baseline was noted in 14 taxane-naïve patients (22.8%) 
and four taxane pretreated patients (8.7%). Commonly noted 
side effects were myelosupression (with 22.4% grade 3/4 
neutropenia), fatigue and peripheral neuropathy.47
Src inhibitors
Dasatinib
The Src-family kinases are the largest family of nonreceptor 
protein tyrosine kinases and are responsible for signal trans-
duction during many cellular activities, including differentia-
tion, adhesion, and migration. Aberrant Src kinase activity 
has been widely implicated in development of prostate and 
several other cancers.48 Src signaling is involved in andro-
gen-induced proliferation of prostate cancer in cancer tissue 
from patients with castration-refractory prostate cancer.49,50 
Aberrant SFK signaling is therefore implicated across mul-
tiple stages and models of prostate cancer. Antiproliferative OncoTargets and Therapy 2010:3 45
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and antiosteoclastic activity from preclinical models show 
potential for dasatinib, an oral SRC and SRC family kinase 
inhibitor, as a targeted therapy for patients with prostate 
cancer.51
Dasatinib was evaluated in a phase II study in 
  chemotherapy-naïve patients with metastatic CRPC.52 
Forty-seven patients were enrolled. Dasatinib was initially 
administered at a dose of 100 mg orally twice daily. After 
the first 25 patients were enrolled, the dosage was reduced 
to 70 mg twice daily for subsequent patients (n = 22). This 
change occurred due to observations in other clinical trials 
with dasatinib where lower doses of dasatinib resulted in 
equal efficacy but improved tolerability. Patients were treated 
with dasatinib until progression of disease, unacceptable 
toxicity at the lowest allowable dose reduction (100 mg 
once daily) despite optimal supportive care. Progression was 
defined as tumor progression by RECIST or by at least one 
definite new lesion on bone scan. The study protocol allowed 
patients with asymptomatic increases in PSA without other 
evidence of progression (RECIST or clinical symptoms), 
to continue therapy. Endpoints included changes in PSA 
levels, bone scans, measurable disease, and markers of bone 
metabolism. Lack of progression according to RECIST and 
bone scan was determined as per Prostate Cancer Working 
Group 2 guidelines, and reported at 12 and 24 weeks. Lack 
of progression was noted in 20 (43%) patients at week 12 
and in nine (19%) patients at week 24. Nearly half of the 
patients showed a decrease in both the markers of bone 
metabolism (n-telopeptide and bone alkaline phosphatase) 
by week 12. This study provides encouraging evidence of 
the activity of dasatinib in chemotherapy-naive patients 
with metastatic CRPC. As a result of this trial, an ongoing 
phase III randomized clinical trial is evaluating the effects 
of the addition of dasatinib to docetaxel on overall survival 
and skeletal-related events.19
Vaccine-based immune therapies
GVAX (CG1940/CG8711)
GVAX immunotherapy for prostate cancer is comprised of 
two prostate tumor cell lines that have been modified to secrete 
granulocyte-macrophage colony-stimulating factor (GM-
CSF), an immune stimulatory cytokine that plays a key role in 
stimulating the body’s immune response, and then irradiated 
for safety. Two phase III trials (VITAL-1 and VITAL-2) have 
evaluated GVAX against docetaxel/prednisone in chemo-
therapy naïve CRPC. Both the study results were presented 
at the 2009 ASCO Genitourinary symposium.53,54 Six hundred 
twenty-six chemotherapy-naïve CRPC patients without 
cancer-related pain were randomized to receive GVAX 
(CG1940/CG8711, 500 million cells prime/300 million cells 
boost doses every two weeks for 13 cycles followed by main-
tenance every four wks) or docetaxel (75 mg/m2 every three 
weeks)/prednisone (10 mg daily). The study was prematurely 
terminated in October 2008 based on the results of a futility 
analysis conducted by the study’s Independent Data Monitor-
ing Committee (IDMC), which determined that the study had 
less than a 30% chance of meeting its predefined primary end-
point of improvement in overall survival. The study completed 
accrual of 626 patients in 2007, and all completed the initial 
six-month treatment period. At the time of study termina-
tion the median follow-up was 66 weeks. Grade 3 or higher 
related adverse events were 8.8% on the vaccine arm vs 43% 
on the docetaxel arm. No difference in median survival was 
observed (20.7 vs 21.7 months; P = 0.78). In the subset of men 
with Halabi predicted survival (HPS) 18 months, median 
survival was prolonged on GVAX compared to docetaxel 
(29.7 vs 27.1 months; P = 0.60). While overall survival was 
not significantly improved compared to chemotherapy, a late 
favorable effect of GVAX is suggested by crossover of the 
Kaplan–Meier survival curve for GVAX above docetaxel at 
approximately 22 months.
In the second phase II trial, VITAL-2, taxane-naïve 
CRPC patients with pain requiring opioid analgesics were 
eligible. Docetaxel (75 mg/m2 every three weeks) was 
given in both arms. Prednisone (10 mg daily) was given 
in the control arm. GVAX (CG1940/CG8711, 500 million 
cells prime/300 million cells boost doses every three weeks 
for 10 cycles) was administered two days following each 
docetaxel infusion in the experimental arm followed by 
maintenance immunotherapy alone every four weeks. 
The study was prematurely terminated in August 2008 
after accrual of 408 patients due to an imbalance in deaths 
between the two treatment arms of the study, with 67 deaths 
in the docetaxel/vaccine arm and 47 deaths in the docetaxel/
prednisone arm. Median predicted survival based on the HPS 
was 13 months in both arms. No significant toxicities in the 
docetaxel/vaccine arm were observed that could explain the 
imbalance in deaths. 85% of deaths were reported as due to 
prostate cancer in both arms. The imbalance was restricted 
to deaths from prostate cancer and to patients with evidence 
of PSA progression at time of death. Overall survival was 
shorter in the docetaxel/vaccine arm with median survival 
of 12.2 months vs 14.1 months in the docetaxel/prednisone 
arm (P = 0.0076). Exploratory analyses to identify subgroups 
of patients with preferential benefit from the investigational 
therapy are underway.OncoTargets and Therapy 2010:3 46
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Active phase III trials in first-line 
chemotherapy for CrPC
Several novel agents and combinations with docetaxel are 
currently being studied in phase III clinical trials for first-line 
chemotherapy for CPRC as listed in Table 2.
Second line chemotherapy 
for CRPC
Patients whose tumors progress through first-line chemo-
therapy have very limited treatment options. Mitoxantrone, 
an anthraquinone structurally related to the anthracyclines, 
may retain some utility in patients who have progressed on 
docetaxel. Indeed, mitoxantrone was the first cytotoxic agent 
to be approved for palliative treatment of men with CRPC.55–57 
Other agents have been tested in a phase II setting and they 
have been reviewed elsewhere.58 There are now several new 
agents being reported and currently tested in this setting.
Docetaxel-based chemotherapy 
combinations
Docetaxel plus bevacizumab
Angiogenesis has a vital role in progression of CRPC. 
The plasma level of vascular endothelial growth factor 
(VEGF) is shown to be an independent predictor of survival 
of CRPC.59 In a phase II study reported by Di Lorenzo and 
colleagues60 of the 20 highly pretreated patients with CPRC 
who received, bevacizumab (10 mg/kg) and docetaxel 
(60 mg/m2) every three weeks, 11 patients (55%) had major 
PSA responses, and three (37.5%) had objective responses. 
Importantly, seven major PSA responses (50% PSA 
decline) were recorded in the same patients who had reported 
a 50% PSA decrease after first-line docetaxel and four 
major PSA responses were observed in patients previously 
nonresponsive to docetaxel alone. This study demonstrates 
that reintroduction of docetaxel after a drug-free interval is 
feasible and effective in docetaxel pretreated patients. The 
role of bevacizumab in docetaxel-pretreated patients needs 
to be further evaluated in a larger, phase III trial. 
Sorafenib, a multitarget tyrosine kinase inhibitor (TKI) 
with antiangiogenic activity via VEGF receptor (VEGFR), 
platelet-derived growth factor receptor (PDGFR), c-Kit, and 
Flt3 as a single agent has been tested on 22 patients with 
CRPC. No biologic response has been observed while on 
treatment, but surprisingly, a PSA decrease has been observed 
in five patients when treatment was stopped. In addition, two 
patients have had a major bone response despite absence of 
biologic response.61
Single cytotoxic agents
Satraplatin
Satraplatin is an orally active third-generation platinum 
compound that has significant activity in cisplatin-resistant 
tumor models. Activity in prostate cancer was suggested in 
early clinical studies.62 Two randomized phase III trials have 
evaluated satraplatin in CRPC. In the first study by Stern-
berg and colleagues,63 satraplatin at a dose of 100 mg/m2 for 
five days every four weeks and prednisone was compared 
Table 2 Active phase III trials in first-line chemotherapy for CRPC19
Study identifier Study drug Mechanism of action Start date Primary endpoint
NCT00255606 Docetaxel/Prednisone 
every 3 weekly vs 2 weekly 
(PrOSTY)
Taxane (antimitotic, 
antimicrotubule agent)
Aug-05 TTF
NCT00887198 Abiraterone Acetate 
+ Prednisone
CYP17A1 inhibitor Apr-09 OS, PFS
NCT00554229 
NCT00617669
ZD4054 (eNTHUSe 
M0; eNTHUSe M1)
endothelin A receptor 
antagonist
Nov-07 OS
NCT00744497 Docetaxel/Prednisone 
+ Dasatinib
Multi-target Tyrosine Kinase 
inhibitor           
Oct-08 OS
NCT00110214 Docetaxel/Prednisone 
+ Bevacizumab
VeGF blocking monoclonal 
antibody
Apr-05 OS
NCT00134056 Docetaxel/Prednisone 
+ Atrasentan
endothelin A receptor 
antagonist
Aug-06 PFS
NCT00626548 Docetaxel/Prednisone 
+ ZD4054
endothelin A receptor 
antagonist
Jan-08 OS
NCT00519285 Docetaxel/Prednisone 
+ Aflibercept (VENICE)
Soluble decoy receptor 
for VeGF
Aug-07 OS
Abbreviations: CrPC, castration-resistant prostate cancer; OS, overall survival; PFS, progression-free survival.OncoTargets and Therapy 2010:3 47
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with prednisone alone. The study was closed prematurely 
because of the sponsor’s decision not to pursue the drug’s 
  development. The ad hoc analysis of the 50 enrolled partici-
pants showed a significant improvement in PFS favoring the 
satraplatin arm (5.2 vs 2.5 months). Median OS also favored 
the satraplatin arm (14.9 vs 11.9 months). These results led 
to a second phase III study, the SPARC trial.64 This study 
used a lower dose of satraplatin (80 mg/m2 for five days 
every four weeks) in combination with prednisone vs pla-
cebo and prednisone. 950 patients with CRPC progressing 
through prior cytotoxic chemotherapy were randomized in a 
2:1 ratio. Significantly higher PSA decline (25.4 vs 12.2%; 
P  0.001), pain response (24.2 vs 13.8%; P  0.005), time 
to pain progression (66.1 vs 22.3 weeks; P  0.001) and 
PFS (11 vs 9.7 weeks) with a 33% reduction in the overall 
risk of disease progression all favored the satraplatin arm. 
However, OS was not statistically significant between the two 
arms (61.3 vs 61.4 weeks; P = 0.80), resulting in a halt in 
further development. Treatment was generally well tolerated, 
with myelo-suppression being the major cause of grade 3 or 
4 adverse events in satraplatin-treated patients.
epothilones
Patupilone, a semi-synthetic derivative of epothilone B, has 
been studied in a multicenter, two-stage design phase II trial in 
patients with CRPC progressing within six months of docetaxel 
treatment. Patupilone was given at a dose of 10 mg/m2 IV 
every three weeks. As reported by Beardsley and colleagues, 
PSA declines of more than 50% were seen in 35 of 78 (45%) 
patients. Grade 3 and 4-related adverse events at this dose 
included fatigue (16%), diarrhea (13%) and anorexia (5%) and 
there were no grade 3 or 4 hematologic adverse events.65 In a 
multicenter phase II study, Ixabepilone (35 mg/m2) given every 
three weeks was compared with mitoxantrone (14 mg/m2) 
given every three weeks. PSA declines of more than 50% were 
seen in 17% of ixabepilone-treated patients and 20% of mito-
xantrone-treated patients. Prior taxane response was associated 
with increased likelihood of second-line therapy response with 
ixabepilone. OS was similar in both groups, 10.4 months for 
ixabepilone and 9.8 months for mitoxantrone.66
Novel targets
endothelin-receptor antagonists
Endothelins (endothelin-1, endothelin-2, and endothelin-
3) are regulators of cell proliferation, vasomotor tone, 
and angiogenesis. The endothelins bind to two receptors, 
endothelin-A and endothelin-B, and play a major role in 
tumor growth, proliferation, apoptosis, angiogenesis, and 
bone metastasis.67 Patients with metastatic prostate cancer 
have elevated levels of plasma endothelin-1 compared with 
patients with organ-confined cancer. Endothelin-A is thought 
to promote osteoblastic activity characteristic of bone metas-
tases in prostate cancer.68
Atrasentan, predominantly an endothelin-A receptor 
antagonist was studied in two phase III trials. In the first 
study, 809 patients with CRPC were randomized to atrasentan 
10 mg daily vs placebo.69 The primary endpoints were time-
to-progression (TTP) which was determined according to 
radiographic and clinical measures. Atrasentan did not reduce 
the risk of disease progression relative to the placebo (hazard 
ratio, 0.89; P = 0.136). In exploratory analyses, however, bone 
alkaline phosphatase and PSA levels were significantly lower 
in the atrasentan arm. Atrasentan generally was tolerated 
well, and the most common adverse events associated with 
treatment were headache, rhinitis, and peripheral edema, 
reflecting the vasodilatory and fluid-retention properties of 
endothelin-A receptor blockade. In a second phase III trial, 
941 men with PSA-only CRPC were randomized to receive 
atrasentan 10 mg daily vs placebo.
Though not statistically significant, fewer patients treated 
with atrasentan experienced disease progression compared 
with placebo (P = 0.288) and the median survival was longer 
for the atrasentan group (P = 0.176). Although it did not meet 
the primary endpoint expectations, atrasentan did have an 
impact on molecular markers that indicate disease progression. 
There was improvement in bone alkaline phosphatase (-1.51 
IU/L (A) vs +2.2 IU/l (P); P = 0.001) and PSA doubling time 
was delayed (P = 0.031). An ongoing phase III study, the 
Southwest Oncology Group trial (SWOG S0421) is evaluat-
ing atrasentan in combination with docetaxel/prednisone as a 
first-line treatment in metastatic CRPC (Table 2).19
Zibotentan (ZD4054) is a selective endothelin-A receptor 
antagonist which was reported in a phase III trials to have 
similar results to atrasentan. No improvement in TTP was 
seen in 308 symptomatic patients with CRPC who were 
randomized to two doses of ZD4054, 15 or 10 mg, once 
daily or placebo. However, an interim analysis revealed an 
improvement in OS (23.5, 24.5 vs 17.3 months for placebo). 
Side effect profile was similar to atrasentan. On the basis of 
these encouraging results, three phase III trials (ENTHUSE) 
involving 2500 patients are currently being conducted in 
CRPC with ZD4054.
Abiraterone
Several preclinical and clinical studies have shown that 
despite being “hormone refractory”, prostate cancer cells OncoTargets and Therapy 2010:3 48
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continue to express high androgen receptor expression and 
thus mediate androgen signaling.5 Abiraterone acetate is a 
potent and a highly selective irreversible inhibitor of cyto-
chrome P-17 (17 a hydroxylase and C17,20-lyase), a dual 
enzyme that blocks adrenal androgen production.70
In a study of 58 patients who had progressive, metastatic 
CRPC and had failed hormonal therapy and up to two cytotoxic 
regimens, including docetaxel, were treated with abiraterone 
(1,000 mg once daily) and prednisone (5 mg twice daily). 
Twenty-five of 56 patients (45%) had a PSA decline 50%. 
Median time to PSA progression was 169 days. The majority 
of abiraterone-related adverse events were grades 1–2 and 
no grade 4 adverse events were reported. Also noted was a 
significantly better PSA response in ketoconazole-naïve post-
docetaxel CRPC population. A randomized phase III pivotal 
study to confirm these results is ongoing.19
MDV3100
MDV3100 is a novel AR antagonist selected for activity in 
prostate cancer model systems with overexpressed AR. In 
contrast to bicalutamide, MDV3100 blocks nuclear translo-
cation of AR and DNA binding, and has no known agonist 
activity when AR is overexpressed.71 Antitumor activity 
of MDV3100 in a phase I/II trial was reported at the 2009 
ASCO annual meeting.20 One hundred forty patients with 
progressive CRPC were enrolled in sequential cohorts of 
3–6 patients at 30, 60, 150, 240, 360, 480, and 600 mg/day. 
Once the safety of a dose was established, enrollment was 
expanded at doses 60 mg/day to include 12 chemotherapy-
naïve and 12 post-chemotherapy patients per cohort. Efficacy 
was assessed by PSA, circulating tumor cells (CTC), and 
time on treatment. PSA declines (50% from baseline) 
were observed at week 12 in 57% (37/65) of naïve and 45% 
(22/49) of post-chemo patients. CTC counts on 101 of 114 
patients showed 92% (56/61) with favorable (5) counts 
pretreatment maintained favorable post-treatment counts, 
while 53% (21/40) converted from unfavorable to favorable 
post-treatment. For post-chemo patients, favorable retention 
was 100% (17/17) and unfavorable to favorable conversion at 
240 and 360 mg/day was 60% (6/10). Based on these results, 
MDV3100 appears to be promising candidate for treatment 
of advanced prostate cancer.
Vaccines based immune therapy
Sipuleucel-T
Sipuleucel-T (Provenge, APC8015) contains mature, autolo-
gous antigen-presenting cells (APCs). APCs are obtained 
from the patient via a standard leukapheresis procedure 
approximately two days before each scheduled infusion. The 
patient’s APCs are co-cultured with a recombinant fusion 
protein containing prostatic acid phosphatase (PAP). The 
activated, antigen-loaded APCs are then infused into the 
patient, where it can potentially stimulate a T cell response 
against prostate cancer cells. The process is performed three 
times over the course of a four-week period. The vaccine 
has been studied in three phase III clinical trials. In the first 
phase III study, D9901, consisting of 127 men with asymp-
tomatic, metastatic CRPC, compared sipuleucel-T every two 
weeks for three cycles with placebo in a 2:1 ratio. The final 
three-year follow-up of the D9901 phase III study showed 
a median survival benefit of 4.5 months and a threefold 
improvement in survival at 36 months for patients who were 
randomized to receive Provenge.72 In another similar phase III 
trial, D9902, 98 men with asymptomatic, metastatic CRPC 
demonstrated a 20% improvement in OS for patients random-
ized to sipuleucel-T. In both studies, the vaccine was well 
tolerated, and the most common adverse events were fever 
and chills. The third phase III trial, D9902B, also known 
as the IMPACT trial (Immunotherapy for Prostate Adeno-
carcinoma Treatment) was a randomized, double-blind, 
placebo-controlled study comparing Provenge with placebo 
in 512 men with CRPC randomized in 2:1 ratio. The results 
were presented at the 2009 American Urological Association 
Annual Meeting. The median overall survival favored the 
vaccine arm with a 4.1-month increase in overall survival 
for patients treated with sipuleucel-T (25.8 vs 21.7 months; 
P = 0.032). Also, 31.7 percent of sipuleucel-T patients were 
alive at three years as compared to 23.0% of placebo patients. 
An integrated analysis of all the three phase III trials, sipu-
leucel-T reduced the risk of death from any cause by 26.5%   
(P  0.001) and extended median overall survival by 
3.9 months compared with placebo. The 36-month overall 
survival was 33% in the sipuleucel-T group and 20% in 
the placebo group. Sipuleucel-T is the first active immuno-
therapy to demonstrate an improvement in overall survival 
for advanced prostate cancer. Given the short duration of the 
therapy (one month) and its favorable benefit-to-risk ratio, 
sipuleucel-T provides an attractive new option for the man-
agement of advanced prostate cancer. The drug is presently 
undergoing evaluation by the FDA for approval.
Active phase iii trials in second-line 
chemotherapy for CrPC
Several novel agents and combinations with docetaxel are 
currently being studied in phase III clinical trials for second-
line chemotherapy for CPRC as listed in Table 3.OncoTargets and Therapy 2010:3 49
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Conclusions
With the benefits of docetaxel-based therapy, more men are 
likely to be offered chemotherapy for CRPC. Treatment deci-
sions for patients with advanced prostate cancer, which were 
largely palliative, have now changed in the light of TAX 327 
and SWOG 9916 studies. The recent updates on the results 
of these studies suggest significant survival advantage and 
also improved quality of life. The exact timing when chemo-
therapy in the metastatic setting should be given is still an 
open question. Several newer docetaxel-based combinations, 
novel targeted treatments and vaccines are quite promising; 
nonetheless, these treatment options have not shown a sig-
nificant survival improvement. Their role in the treatment of 
CRPC still needs to be validated by phase III trials, which 
are currently ongoing. Also, the exact utility and relevance 
of novel biomarkers calls for a larger prospective validation. 
The future is very promising for the clinical trials of today to 
become the standard-of-care treatments of tomorrow. Over 
the past decade, our understanding of molecular basis of 
androgen resistance and patho-biology of CRPC has been 
advancing, leading to novel agents that specifically target 
these pathways. In view of the multitude of questions still 
unanswered, every patient with CRPC should be encouraged 
to participate in clinical trials. Patients, physicians and fami-
lies should support each other in the quest to eradicate and 
cure more patients and minimize mortality of CRPC.
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